<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17324" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Albendazole</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Malik</surname>
            <given-names>Kashif</given-names>
          </name>
          <aff>Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dua</surname>
            <given-names>Anterpreet</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kashif Malik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anterpreet Dua declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17324.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Albendazole is an FDA-approved medication for treating a variety of parasitic worm infections. Albendazole is an antihelminthic medication with numerous indications such as cystic hydatid disease of the liver, lung, and peritoneum resulting from the larval form of the dog tapeworm, Echinococcus granulosus. Albendazole also has approval for treating parenchymal neurocysticercosis secondary to active lesions caused by infection with larval forms of the pork tapeworm, Taenia solium. This activity will discuss the role of the interprofessional team in the use of this medication.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of albendazole.</p></list-item><list-item><p>Describe the potential adverse effects of albendazole.</p></list-item><list-item><p>Review the approved and off-label indications of albendazole.</p></list-item><list-item><p>Identify some interprofessional team strategies for improving care coordination and communication to advance albendazole therapy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17324&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17324">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17324.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Albendazole is an FDA-approved medication for the treatment of a variety of parasitic worm infections. Albendazole is an antihelminthic medication with numerous indications such as cystic hydatid disease of the liver, lung, and peritoneum resulting from the larval form of the dog tapeworm, <italic toggle="yes">Echinococcus granulosus</italic>. Albendazole also has approval for treating parenchymal neurocysticercosis secondary to active lesions caused by infection with larval forms of the pork tapeworm, <italic toggle="yes">Taenia solium</italic>. It can also be a valuable agent for the treatment of pinworm disease caused by <italic toggle="yes">Enterobius vermicularis</italic>.</p>
        <p>Albendazole is used to treat Trichuriasis (<italic toggle="yes">Trichuris trichiuria</italic>), Filiariasis, Ascariasis (<italic toggle="yes">Ascaris lumbricoides</italic>), and metronidazole-resistant Giardiasis (<italic toggle="yes">Giardia</italic>
<italic toggle="yes">duodenalis</italic>)<italic toggle="yes">.</italic>&#x000a0;</p>
        <p>Finally, it can be prescribed as a treatment for Trichinosis (<italic toggle="yes">Trichinella spiralis</italic>), hookworms (<italic toggle="yes">Ancylostoma</italic>
<italic toggle="yes">sp.</italic> and&#x000a0;<italic toggle="yes">Necator sp.</italic>), and&#x000a0;Strongyloidiasis (<italic toggle="yes">Strongyloides stercoralis</italic>).<xref ref-type="bibr" rid="article-17324.r1">[1]</xref></p>
        <p>Albendazole has also been the topic of recent investigation as a potential anticancer agent due to its limited toxicity to normal cells but high toxicity to both tumor and parasitic cells.<xref ref-type="bibr" rid="article-17324.r2">[2]</xref>&#x000a0;Recent studies have created nanoformulations of albendazole and conjugated the drug to nano-carriers to improve solubility and increase drug delivery to tumor cells.<xref ref-type="bibr" rid="article-17324.r2">[2]</xref></p>
        <p>Albendazole and mebendazole have demonstrated anticancer properties in vitro and in animal models. Both have demonstrated anticancer properties against the following solid tumor cancers: breast, head and neck, colorectal, melanoma, ovary, and prostate. There is also limited clinical data on albendazole and mebendazole&#x02019;s anticancer properties. Neutropenia is a limiting side effect of prolonged high dose albendazole pharmacotherapy. Mebendazole appears less likely to cause neutropenia.<xref ref-type="bibr" rid="article-17324.r3">[3]</xref></p>
        <p>Keller L. et al. conducted double-blind, randomized controlled trials on the effectiveness of albendazole-ivermectin versus albendazole-placebo in the treatment of <italic toggle="yes">Trichuris trichiura</italic>. The patients, ages 6 to 60, were from Lao People's Democratic Republic (Laos) and Tanzania (Pemba Island). In Laos, 466 patients received the combination of albendazole-ivermectin, and 413 patients received albendazole-placebo treatment. In Tanzania, 558 patients received the combination of albendazole-ivermectin, and 515 patients received albendazole-placebo treatment. Patients were assessed at six months and twelve months post-treatment. A minimum of one stool specimen was collected from each patient who underwent Kato-Katz assessment, and helminth egg reduction rates, reinfection rates, and cure rates were determined. Patients who were helminth positive after six months received additional treatment. The helminth egg reduction rates in patients from Laos at six months were 99 vs. 79.6 % in albendazole-ivermectin versus albendazole-placebo, respectively. The cure rates were 65.8 vs. 13.4% in albendazole-ivermectin versus albendazole-placebo, respectively. The helminth egg reduction rates in patients from Tanzania at six months were 84.9 vs. 21.2% in albendazole-ivermectin versus albendazole-placebo, respectively. The cure rates were 17.8 vs. 1.4% in albendazole-ivermectin versus albendazole-placebo, respectively. The reinfection rate was 10% in Laos and 100% in Tanzania at twelve months for the albendazole-placebo cohort. Keller L. et al. concluded that albendazole-ivermectin treatment was superior to albendazole-placebo treatment regarding <italic toggle="yes">Trichuris trichiura</italic> egg reduction rates, reinfection rates, and cure rates.<xref ref-type="bibr" rid="article-17324.r4">[4]</xref></p>
      </sec>
      <sec id="article-17324.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Albendazole sulfoxide, the active metabolite of albendazole, causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae. The metabolite binds to the B-tubulin subunit of the helminth's microtubules and thus inhibits microtubule polymerization.<xref ref-type="bibr" rid="article-17324.r5">[5]</xref>&#x000a0;</p>
        <p>Albendazole also causes impaired glucose utilization and causes a decrease in the parasite's glycogen stores. At high concentrations, albendazole inhibits parasitic metabolic pathways such as the Kreb cycle by inhibiting key enzymes such as malate dehydrogenase. A subsequent decrease in ATP production occurs, which causes energy depletion, leading to the immobilization of the&#x000a0;parasite and subsequent death.<xref ref-type="bibr" rid="article-17324.r5">[5]</xref></p>
      </sec>
      <sec id="article-17324.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Albendazole comes in a variety of formulations ranging from tablets to oral solutions. A limiting factor&#x000a0;in dosing albendazole is its poor solubility and absorption in the human body.<xref ref-type="bibr" rid="article-17324.r6">[6]</xref>&#x000a0;Consequently, albendazole should be administered with a high-fat meal to improve its bioavailability.<xref ref-type="bibr" rid="article-17324.r6">[6]</xref>&#x000a0;To treat an intraluminal infection, albendazole administration should be on an empty stomach to maximize absorption. The tablets can be crushed or chewed and then swallowed with a drink of water if the patient has difficulty swallowing. An oral suspension of albendazole is also an option if the patient has swallowing dysfunction or is at risk for aspiration. Researchers are developing new formulations of albendazole that have micro-emulsifying delivery systems and increased lipid-solubility to maximize the therapeutic efficacy of the drug.<xref ref-type="bibr" rid="article-17324.r7">[7]</xref></p>
        <p>Care is necessary when albendazole is coadministered with medications that interact with the cytochrome P450 pathway as the CYP450 system of enzymes metabolizes albendazole. CYP450 inducing medications such as phenobarbital, phenytoin, rifampin, and carbamazepine can lower the concentration of albendazole by as much as 50%.<xref ref-type="bibr" rid="article-17324.r5">[5]</xref>&#x000a0;CYP450 inhibitors such as cimetidine and grapefruit juice can increase the concentration and availability of albendazole by as much as 50% as well.<xref ref-type="bibr" rid="article-17324.r8">[8]</xref></p>
        <p>Commonly, clinicians coadminister steroids such as dexamethasone with albendazole to treat neuro-helminth infections to increase the bioavailability of albendazole, reduce inflammation, and decrease cerebral edema.<xref ref-type="bibr" rid="article-17324.r9">[9]</xref>&#x000a0;Corticosteroids have demonstrated a capacity to increase the efficacy of the treatment, reduce complications, and improve patient outcomes when coadministered with albendazole.<xref ref-type="bibr" rid="article-17324.r9">[9]</xref></p>
      </sec>
      <sec id="article-17324.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects accompanying albendazole use are headaches and elevated liver enzymes, with 10% to 20% of patients experiencing elevated liver enzymes.<xref ref-type="bibr" rid="article-17324.r10">[10]</xref><xref ref-type="bibr" rid="article-17324.r11">[11]</xref>&#x000a0;Some other side effects of albendazole include abdominal pain, nausea, vomiting, and fever. A small percentage of patients may experience a hypersensitivity reaction such as hives and pruritus to the drug.&#x000a0;There are reports of alopecia and telogen effluvium in the literature as rare side effects of albendazole therapy. Fortunately, alopecia and telogen effluvium usually reverse after completing the treatment.<xref ref-type="bibr" rid="article-17324.r10">[10]</xref></p>
        <p>Other serious side effects include&#x000a0;leukopenia, anemia, thrombocytopenia, and pancytopenia, with patients who have preexisting liver damage or dysfunction at the highest risk for developing these conditions.<xref ref-type="bibr" rid="article-17324.r12">[12]</xref>&#x000a0;The most likely mechanism is that albendazole-induced myelosuppression results from the drug's beta-tubulin inhibition affecting the host's microtubules and thus inhibiting the activity of actively dividing human cells such as white blood cells.<xref ref-type="bibr" rid="article-17324.r12">[12]</xref></p>
        <p>Patients with neuro-helminth infection may experience symptoms such as focal neurologic deficits, seizures, and headaches more frequently compared to other parasitic infections due to the destruction of helminthic larvae and cysts in the brain. They also may experience meningeal signs and increased intracranial pressure due to the local inflammatory reaction from parasite death. Mitigating these symptoms is possible with the coadministration of steroids and anticonvulsant medication.&#x000a0;</p>
      </sec>
      <sec id="article-17324.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Albendazole is contraindicated in patients with a history of hypersensitivity to albendazole, benzimidazoles, or any component of the formulation. Clinicians should use the drug with caution in patients with active liver disease or dysfunction because the liver metabolizes the drug via the CYP450 system.<xref ref-type="bibr" rid="article-17324.r5">[5]</xref>&#x000a0;Also, care is in order if the patient has biliary obstruction as the drug gets significantly excreted in bile.</p>
        <p>The FDA classified albendazole as a category C drug under the prior pregnancy rating system, which states the drug should be avoided during pregnancy and reserved only for use in pregnant patients if there is not an acceptable alternative available. Studies in rats have shown some teratogenic effects in the offspring of rats that received the drug; however, some studies of pregnant patients that received albendazole did not show an increased risk of teratogenicity with exposure to the drug. More research is necessary as there are very few articles in the literature about the potential effects on pregnancy and the developing fetus.<xref ref-type="bibr" rid="article-17324.r13">[13]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17324.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Liver function tests and CBC with differential should be performed at the start of a 28-day cycle and every two weeks during therapy due to the risk of pancytopenia and anemia.<xref ref-type="bibr" rid="article-17324.r13">[13]</xref><xref ref-type="bibr" rid="article-17324.r12">[12]</xref>&#x000a0;Patients with a predisposition for leukopenia and pancytopenia, such as patients with recent chemotherapy, should be observed closely due to the potential of albendazole-induced myelosuppression. Patients with liver disease require more frequent monitoring because the drug is metabolized primarily by the liver.<xref ref-type="bibr" rid="article-17324.r6">[6]</xref>&#x000a0;Before initiating therapy, ophthalmic exams for retinal lesions should also be performed in patients with neurocysticercosis because the destruction of parasites in the eye can cause retinal damage.&#x000a0;</p>
      </sec>
      <sec id="article-17324.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Albendazole's low solubility prevents it from being absorbed in large enough quantities to be toxic to humans.&#x000a0;There is no specific antidote for albendazole overdose.<xref ref-type="bibr" rid="article-17324.r14">[14]</xref></p>
      </sec>
      <sec id="article-17324.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Albendazole is one of the most used antiparasitic drugs used throughout the world due to its low cost and high efficacy. Most of the time, this drug is well-tolerated with very few side effects; however, this drug should not be used without physician monitoring or approval due to the risk of severe side effects such as pancytopenia; this effort requires an interprofessional team. Patients with liver dysfunction require regular liver function tests and monitoring due to the increased risk of side effects.&#x000a0;[Level 3]</p>
        <p>Pharmacists can&#x000a0;make a significant contribution to the care of patients&#x000a0;taking albendazole by creating the proper formulation for the patient to administer. For example, patients with high aspiration risks or swallowing dysmotility can benefit from oral suspensions, and children can benefit from dissolved tablets or oral suspensions as well to increase their adherence to drug therapy. They can also check for potential drug-drug interactions and serve as a point of patient counsel about the medication and how to take it.</p>
        <p>For patients with neurologic involvement, ophthalmologists can observe potential retinal progression and resolution of the disease. Infectious disease specialists can coordinate care with primary care providers to ensure proper infection treatment. Nurses are integral in the treatment process as they are often the direct interface with the patient and can obtain information regarding medication side effects and patient adherence. With interprofessional management and monitoring, albendazole therapy has its best chance of achieving positive patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-17324.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17324&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17324">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17324/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17324">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17324.s11">
        <title>References</title>
        <ref id="article-17324.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henriquez-Camacho</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gotuzzo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Echevarria</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Terashima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Samalvides</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Molina</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Plana</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Jan</month>
            <day>18</day>
            <volume>2016</volume>
            <issue>1</issue>
            <fpage>CD007745</fpage>
            <pub-id pub-id-type="pmid">26778150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Movahedi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>ZP</given-names>
              </name>
            </person-group>
            <article-title>Nanoformulations of albendazole as effective anticancer and antiparasite agents.</article-title>
            <source>Nanomedicine (Lond)</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>20</issue>
            <fpage>2555</fpage>
            <page-range>2555-2574</page-range>
            <pub-id pub-id-type="pmid">28954575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chai</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.</article-title>
            <source>Korean J Parasitol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-225</page-range>
            <pub-id pub-id-type="pmid">34218593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Welsche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sayasone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ame</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hattendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>H&#x000fc;rlimann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keiser</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcomes of ivermectin-albendazole versus albendazole alone against soil-transmitted helminths: Results from randomized controlled trials in Lao PDR and Pemba Island, Tanzania.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>e0009561</fpage>
            <pub-id pub-id-type="pmid">34191812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkatesan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Albendazole.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-7</page-range>
            <pub-id pub-id-type="pmid">9533454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Development and application of anthelminthic drugs in China.</article-title>
            <source>Acta Trop</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>200</volume>
            <fpage>105181</fpage>
            <pub-id pub-id-type="pmid">31542370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawatdee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atipairin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sae Yoon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srichana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Changsan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Suwandecha</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Formulation Development of Albendazole-Loaded Self-Microemulsifying Chewable Tablets to Enhance Dissolution and Bioavailability.</article-title>
            <source>Pharmaceutics</source>
            <year>2019</year>
            <month>Mar</month>
            <day>20</day>
            <volume>11</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30897738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schipper</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Koopmans</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Butter</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Van Boxtel</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>260</fpage>
            <page-range>260-3</page-range>
            <pub-id pub-id-type="pmid">12139218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Carpio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kelvin</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?</article-title>
            <source>J Clin Pharmacol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-7</page-range>
            <pub-id pub-id-type="pmid">24443292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veraldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Francia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>La Vela</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nazzaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbareschi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Telogen effluvium after oral albendazole.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-7</page-range>
            <pub-id pub-id-type="pmid">22420487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Speich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ame</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bogoch</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Alles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huwyler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Albonico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hattendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Utzinger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keiser</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>277</fpage>
            <page-range>277-84</page-range>
            <pub-id pub-id-type="pmid">25589326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xing</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Seto</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Fatal pancytopenia due to albendazole treatment for strongyloidiasis.</article-title>
            <source>IDCases</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>112</fpage>
            <page-range>112-116</page-range>
            <pub-id pub-id-type="pmid">29942764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Foetal outcomes after exposure to albendazole in early pregnancy.</article-title>
            <source>J Obstet Gynaecol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>1108</fpage>
            <page-range>1108-1111</page-range>
            <pub-id pub-id-type="pmid">28760057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dayan</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics.</article-title>
            <source>Acta Trop</source>
            <year>2003</year>
            <month>May</month>
            <volume>86</volume>
            <issue>2-3</issue>
            <fpage>141</fpage>
            <page-range>141-59</page-range>
            <pub-id pub-id-type="pmid">12745134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtiss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cobos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sicco</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Seminara</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Acute Alopecia Associated With Albendazole Toxicosis.</article-title>
            <source>Cutis</source>
            <year>2022</year>
            <month>May</month>
            <volume>109</volume>
            <issue>5</issue>
            <fpage>E43</fpage>
            <page-range>E43-E45</page-range>
            <pub-id pub-id-type="pmid">35856765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Albendazole for Neurocysticercosis in Children: How Long is Long Enough?</article-title>
            <source>Indian Pediatr</source>
            <year>2022</year>
            <month>Dec</month>
            <day>15</day>
            <volume>59</volume>
            <issue>12</issue>
            <fpage>909</fpage>
            <page-range>909-910</page-range>
            <pub-id pub-id-type="pmid">36511204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17324.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Z&#x000f6;eller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jarvi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Efficacy and Safety of Albendazole and Other Benzimidazole Anthelmintics for Rat Lungworm Disease (Neuroangiostrongyliasis): A Systematic Analysis of Clinical Reports and Animal Studies.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Apr</month>
            <day>09</day>
            <volume>74</volume>
            <issue>7</issue>
            <fpage>1293</fpage>
            <page-range>1293-1302</page-range>
            <pub-id pub-id-type="pmid">34448480</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
